The introduction of Intraocular Anti-VEGFs agents have significantly improved the management of a wide variety of neovscular ocular diseases including retinopathy of prematurity (ROP). In our hands, monotherapy treatment with intravitreal bevacizumab (IVB) is a favourable treatment modality in management of threshold ROP. In eyes with iris rubeosis, rigid pupils and vitreous haze where it is difficult to visualize the fundus and perform...

Read More